Tensor clustering with algebraic constraints gives interpretable groups of crosstalk mechanisms in breast cancer.


Journal

Journal of the Royal Society, Interface
ISSN: 1742-5662
Titre abrégé: J R Soc Interface
Pays: England
ID NLM: 101217269

Informations de publication

Date de publication:
28 02 2019
Historique:
entrez: 9 4 2019
pubmed: 9 4 2019
medline: 5 3 2020
Statut: ppublish

Résumé

We introduce a tensor-based clustering method to extract sparse, low-dimensional structure from high-dimensional, multi-indexed datasets. This framework is designed to enable detection of clusters of data in the presence of structural requirements which we encode as algebraic constraints in a linear program. Our clustering method is general and can be tailored to a variety of applications in science and industry. We illustrate our method on a collection of experiments measuring the response of genetically diverse breast cancer cell lines to an array of ligands. Each experiment consists of a cell line-ligand combination, and contains time-course measurements of the early signalling kinases MAPK and AKT at two different ligand dose levels. By imposing appropriate structural constraints and respecting the multi-indexed structure of the data, the analysis of clusters can be optimized for biological interpretation and therapeutic understanding. We then perform a systematic, large-scale exploration of mechanistic models of MAPK-AKT crosstalk for each cluster. This analysis allows us to quantify the heterogeneity of breast cancer cell subtypes, and leads to hypotheses about the signalling mechanisms that mediate the response of the cell lines to ligands.

Identifiants

pubmed: 30958184
doi: 10.1098/rsif.2018.0661
pmc: PMC6408352
doi:

Substances chimiques

Proto-Oncogene Proteins c-akt EC 2.7.11.1
Mitogen-Activated Protein Kinase Kinases EC 2.7.12.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

20180661

Références

Sci Data. 2017 Nov 07;4:170166
pubmed: 29112189
J R Soc Interface. 2016 Aug;13(121):
pubmed: 27581482
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J R Soc Interface. 2012 Aug 7;9(73):1925-33
pubmed: 22262815
Oncogene. 1997 Sep 18;15(12):1385-94
pubmed: 9333014
Science. 2006 May 26;312(5777):1175-8
pubmed: 16728632
Comput Methods Programs Biomed. 2007 Oct;88(1):52-61
pubmed: 17707944
Br J Cancer. 2004 Jul 19;91(2):355-8
pubmed: 15188009
Mol Cancer Res. 2007 Feb;5(2):195-201
pubmed: 17314276
Oncogene. 1999 Nov 25;18(50):7110-4
pubmed: 10597312
Mol Syst Biol. 2009;5:239
pubmed: 19156131
PLoS One. 2015 Apr 15;10(4):e0121396
pubmed: 25875127
Mol Cell. 2002 May;9(5):957-70
pubmed: 12049733
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2724-9
pubmed: 22003129
CPT Pharmacometrics Syst Pharmacol. 2015 Mar;4(3):e00019
pubmed: 26225238
PLoS Comput Biol. 2016 Apr 01;12(4):e1004827
pubmed: 27035903
Nat Methods. 2016 Jun;13(6):521-7
pubmed: 27135972
Nat Genet. 2016 Sep;48(9):1094-100
pubmed: 27479908
Nat Cell Biol. 2009 Dec;11(12):1458-64
pubmed: 19935650
J Cell Physiol. 2011 Nov;226(11):2762-81
pubmed: 21302297
Sci Signal. 2013 Aug 13;6(288):ra68
pubmed: 23943608
Sci Signal. 2010 Jul 27;3(132):ra56
pubmed: 20664065
Oncogene. 2011 Jun 2;30(22):2547-57
pubmed: 21278786
IEEE/ACM Trans Comput Biol Bioinform. 2004 Jan-Mar;1(1):24-45
pubmed: 17048406
Front Physiol. 2012 Sep 18;3:355
pubmed: 23060802
J R Soc Interface. 2014 Dec 6;11(101):20140940
pubmed: 25297320
Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10078-83
pubmed: 8816754
Cell. 1995 Jan 27;80(2):179-85
pubmed: 7834738
J Mol Cell Biol. 2012 Jun;4(3):153-63
pubmed: 22561840
BMC Biol. 2014 Mar 21;12:20
pubmed: 24655548
Nat Rev Cancer. 2015 Sep;15(9):515-27
pubmed: 26289315
Mol Oncol. 2010 Jun;4(3):209-29
pubmed: 20537966
Nature. 2012 Apr 04;486(7403):395-9
pubmed: 22495314
Curr Opin Obstet Gynecol. 2013 Feb;25(1):40-8
pubmed: 23222093
Sci Signal. 2013 Sep 24;6(294):ra84
pubmed: 24065145
Cell. 2013 Feb 28;152(5):945-56
pubmed: 23452846
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):12755-60
pubmed: 20615936

Auteurs

Anna Seigal (A)

1 Department of Mathematics, University of California , Berkeley, CA 94702 , USA.

Mariano Beguerisse-Díaz (M)

2 Mathematical Institute, University of Oxford , Oxford OX2 6GG , UK.

Birgit Schoeberl (B)

3 Novartis Institutes for BioMedical Research , Cambridge, MA 02139 , USA.

Mario Niepel (M)

4 Ribon Therapeutics , Lexington, MA 02421 , USA.

Heather A Harrington (HA)

2 Mathematical Institute, University of Oxford , Oxford OX2 6GG , UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH